Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI-Reference-Cited by-同舟云学术

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Published:2011-02-11 Issue:5 Volume:121 Page:597-609
ISSN:0001-6322
Container-title:Acta Neuropathologica
language:en
Short-container-title:Acta Neuropathol

Author:

Shaw Leslie M., ,Vanderstichele Hugo,Knapik-Czajka Malgorzata,Figurski Michal,Coart Els,Blennow Kaj,Soares Holly,Simon Adam J.,Lewczuk Piotr,Dean Robert A.,Siemers Eric,Potter William,Lee Virginia M.-Y.,Trojanowski John Q.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology (clinical),Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00401-011-0808-0.pdf

Reference44 articles.

1. Andreasen N, Hesse C, Davidsson P et al (1999) Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56:673–680

2. Bates D, Maechler M (2010) lme4: Linear mixed-effects models using S4 classes. R package version 0.999375-34. http://CRAN.R-project.org/package=lme4

3. Bjerke M, Portelius E, Minthon L et al (2010) Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alz Dis (in press)

4. Buerger K, Ewers M, Pirttila T et al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 129:3035–3041

5. Buerger K, Frisoni G, Uspenskaya O et al (2009) Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 44:579–585

Cited by 257 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease;Alzheimer's & Dementia;2024-06-19

2. Definition and analysis of gray matter atrophy subtypes in mild cognitive impairment based on data-driven methods;Frontiers in Aging Neuroscience;2024-06-04

3. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease;Alzheimer's & Dementia;2024-04-21

4. Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients;Alzheimer's Research & Therapy;2024-04-03

5. Alzheimer's disease cerebrospinal fluid biomarkers and kidney function in normal and cognitively impaired older adults;Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring;2024-04